Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
- Revenue in USD (TTM)5.90m
- Net income in USD-87.96m
- Incorporated2004
- Employees73.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tyra Biosciences Inc | 0.00 | -80.88m | 1.10bn | 49.00 | -- | 2.92 | -- | -- | -1.69 | -1.69 | 0.00 | 7.13 | 0.00 | -- | -- | 0.00 | -25.18 | -- | -25.81 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
Praxis Precision Medicines Inc | 1.77m | -123.74m | 1.11bn | 82.00 | -- | 2.65 | -- | 626.56 | -10.26 | -10.26 | 0.1393 | 23.60 | 0.0062 | -- | -- | 21,597.56 | -43.07 | -74.04 | -46.74 | -85.12 | -- | -- | -6,987.01 | -24,589.25 | -- | -- | 0.00 | -- | -- | -- | 42.40 | -- | -4.52 | -- |
Arcutis Biotherapeutics Inc | 132.06m | -198.76m | 1.14bn | 296.00 | -- | 6.12 | -- | 8.67 | -2.18 | -2.18 | 1.36 | 1.60 | 0.3451 | 0.8334 | 4.36 | 446,155.40 | -51.93 | -65.64 | -58.68 | -71.72 | 92.32 | -- | -150.51 | -1,513.03 | 8.19 | -5.94 | 0.5223 | -- | 1,517.09 | -- | 15.83 | -- | -- | -- |
Mesoblast Ltd (ADR) | 5.90m | -87.96m | 1.16bn | 73.00 | -- | 2.37 | -- | 197.39 | -0.8761 | -0.8761 | 0.0598 | 4.21 | 0.0088 | -- | 3.21 | 80,849.31 | -13.14 | -12.62 | -14.38 | -13.97 | -166.30 | -109.14 | -1,490.28 | -692.63 | -- | -3.54 | 0.1984 | -- | -21.32 | -18.80 | -7.41 | -- | -0.5802 | -- |
Travere Therapeutics Inc | 177.64m | -383.45m | 1.17bn | 380.00 | -- | 77.03 | -- | 6.57 | -4.99 | -1.88 | 2.31 | 0.1981 | 0.2759 | 0.7613 | 7.92 | 467,484.20 | -59.56 | -36.95 | -74.41 | -44.77 | 94.70 | 95.92 | -215.85 | -165.79 | 2.99 | -- | 0.9615 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
Wave Life Sciences Ltd | 110.50m | -73.74m | 1.17bn | 266.00 | -- | -- | -- | 10.59 | -0.5796 | -0.5796 | 0.9275 | 0.0359 | 0.5036 | -- | -- | 415,413.50 | -33.49 | -56.98 | -117.16 | -102.38 | -- | -- | -66.50 | -353.20 | -- | -- | 0.00 | -- | 3,005.10 | 51.04 | 64.46 | -- | -35.44 | -- |
Cogent Biosciences Inc | 0.00 | -227.05m | 1.18bn | 164.00 | -- | 4.53 | -- | -- | -2.48 | -2.48 | 0.00 | 3.41 | 0.00 | -- | -- | 0.00 | -55.22 | -49.53 | -60.02 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
Day One Biopharmaceuticals Inc | 8.19m | -167.48m | 1.19bn | 169.00 | -- | 3.88 | -- | 145.48 | -1.94 | -1.94 | 0.0948 | 3.50 | 0.0193 | -- | -- | 52,851.61 | -39.35 | -- | -45.70 | -- | 91.37 | -- | -2,044.43 | -- | 4.09 | -- | 0.00 | -- | -- | -- | -32.87 | -- | -- | -- |
Bicara Therapeutics Inc | 0.00 | -64.84m | 1.20bn | 32.00 | -- | -- | -- | -- | -1.25 | -1.25 | 0.00 | 3.72 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.36 | -- | -- | -- |
Gyre Therapeutics Inc | 165.85m | -79.66m | 1.21bn | 593.00 | -- | 18.38 | -- | 7.31 | -0.8638 | -0.8638 | 1.43 | 0.7056 | 2.49 | -- | 17.81 | 279,674.50 | -103.20 | -73.59 | -167.87 | -99.94 | 96.15 | -- | -41.48 | -205.62 | 3.07 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
Cassava Sciences Inc | 0.00 | -15.37m | 1.22bn | 29.00 | -- | 6.45 | -- | -- | -0.4054 | -0.4054 | 0.00 | 3.94 | 0.00 | -- | -- | 0.00 | -6.97 | -30.74 | -8.35 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
Enliven Therapeutics Inc | 0.00 | -82.83m | 1.30bn | 52.00 | -- | 4.25 | -- | -- | -1.93 | -1.93 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -26.91 | -42.26 | -28.35 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
Longboard Pharmaceuticals Inc | 0.00 | -64.74m | 1.30bn | 50.00 | -- | 4.40 | -- | -- | -2.16 | -2.16 | 0.00 | 7.58 | 0.00 | -- | -- | 0.00 | -34.15 | -- | -36.32 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Group One Trading LPas of 31 Mar 2024 | 143.67k | 0.13% |
Summit X LLCas of 31 Mar 2024 | 139.75k | 0.12% |
Penbrook Management LLCas of 30 Jun 2024 | 124.93k | 0.11% |
Prosperity Wealth Management, Inc.as of 31 Mar 2024 | 77.35k | 0.07% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 62.16k | 0.05% |
Wells Fargo Advisors Financial Network LLCas of 31 Mar 2024 | 59.21k | 0.05% |
HRT Financial LLCas of 31 Mar 2024 | 57.82k | 0.05% |
Susquehanna Financial Group LLLPas of 31 Mar 2024 | 57.51k | 0.05% |
Lazari Capital Management, Inc.as of 31 Mar 2024 | 50.17k | 0.04% |
LPL Financial LLCas of 30 Jun 2024 | 29.99k | 0.03% |